Guideline for use and disclosure of biomarkers of dementia

Takeshi Ikeuchi

Department of Molecular Genetics, Brain Research Institute, Niigata University

Clinical applications of cerebrospinal fluid and blood-based biomarkers has been expanding over the last decade.　Biomarkers have been shown to be a useful tool for early diagnosis and differential diagnosis of dementia by estimating underlying neuropathological changes in clinical practice.　Biomarkers are also utilized for clinical research and trials for selecting appropriate subjects and evaluating efficacy of the developing drugs.　The biomarker tests will become mandatory when disease-modifying therapy using anti-amyloid antibodies is approved for clinical use.　Careful counseling through the diagnostic process and sufficient follow-up support after the disclosure of the biomarker results is highly recommended.　This review paper is aimed to provide guidance of appropriate use and disclosure of biomarkers for dementia.

Address correspondence to Address correspondence to Dr. Takeshi Ikeuchi, Department of Molecular Genetics Brain Research Institute, Niigata University （1-757 Asahimachi, Niigata 951-8585, Japan）